FDA Issues More Warning Letters, Drops Follow-Up Letters In Favor Of Action
This article was originally published in The Tan Sheet
Executive Summary
FDA will warn firms only once - if at all - before taking stronger enforcement actions to stop systematic quality and safety problems, said Howard Sklamberg, director of the Office of Enforcement at the Office of Regulatory Affairs